Your browser doesn't support javascript.
loading
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe, Stephen Loucian; Willis, Brian A; Hawdon, Anne; Natanegara, Fanni; Chua, Laiyi; Foster, Joanne; Shcherbinin, Sergey; Ardayfio, Paul; Sims, John R.
Affiliation
  • Lowe SL; Eli Lilly and Company Lilly Centre for Clinical Pharmacology Singapore Singapore.
  • Willis BA; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
  • Hawdon A; Eli Lilly and Company Limited Erl Wood Manor, Windlesham United Kingdom.
  • Natanegara F; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
  • Chua L; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
  • Foster J; Eli Lilly and Company Limited Erl Wood Manor, Windlesham United Kingdom.
  • Shcherbinin S; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
  • Ardayfio P; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
  • Sims JR; Eli Lilly and Company Lilly Corporate Center DC 1532 Indianapolis Indiana USA.
Alzheimers Dement (N Y) ; 7(1): e12112, 2021.
Article in En | MEDLINE | ID: mdl-33614890
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Alzheimers Dement (N Y) Year: 2021 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Alzheimers Dement (N Y) Year: 2021 Document type: Article Country of publication: Estados Unidos